Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold

Four months ago, the FDA placed a clinical hold on Celyad’s CAR-T trial for colorectal cancer after two patients died during the study. Regulators have now lifted the hold, allowing the Belgian company’s trial to set sail once again.